Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277017 · ClinicalTrials.gov registry record · Phase 1
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00277017 is a Phase 1 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 15 participants.
The verdict
NCT00277017, a Phase 1 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment. We also wish to see if the addition of Thalidomide will increase the effectiveness of the already established treatment regimen.
Interventions
- DRUG 5-Flourouracil, Interferon-a, IL-2 and Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2000-09 |
| Est. Completion | 2005-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277017
The ClinicalTrials.gov registry entry for NCT00277017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 5-Flourouracil, Interferon-a, IL-2 and Thalidomide is the first listed.
NCT00277017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00277017 about?
NCT00277017 is a clinical study titled "Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma". The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment. We also wish to see if the addition of Thalidomide will increase the effectiv...
What is the current status of trial NCT00277017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2000-09. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00277017?
The interventions under investigation include: 5-Flourouracil, Interferon-a, IL-2 and Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00277017?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.